Erratum: Early response to sibutramine in patients not meeting current label criteria: Preliminary analysis of SCOUT lead-in period (Obesity 18 (987-994) DOI: 10.1038/oby.2009.327);Early response to sibutramine in patients not meeting current label criteria: Preliminary analysis of SCOUT lead-in period

Obesity

Volumn 18, Issue 5, 2010, Pages 987-994

  Caterson, Ian ^a   Coutinho, Walmir ^b   Finer, Nick ^c   Van Gaal, Luc ^d   Maggioni, Aldo ^e   Torp Pedersen, Christian ^f   Sharma, Arya M ^g   Ge, Hong ^h   Santoro, Donatella ^h   Shepherd, Gillian ^h   James, Philip ⁱ  

^a UNIVERSITY OF SYDNEY   (Australia)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e ANMCO RESEARCH CENTER   (Italy)

^f BISPEBJERG HOSPITAL   (Denmark)

^g UNIVERSITY OF ALBERTA   (Canada)

^h ABBOTT LABORATORIES   (United States)

ⁱ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77951665530     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2009.440     Document Type: Erratum

References (19)

1. World Health Organization. Obesity in Europe http://www.euro.who.int/ obesity(2007).
2. Centers for Disease Control and Prevention. US Obesity Trends 1985-2007 http://www.cdc.gov/nccdphp/dnpa/obesity/trend/maps/index.htm (2008).
3. Ogden CL, Carroll MD, Curtin LR et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006;295:1549-1555.
4. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults\The Evidence Report. National Institutes of Health. Obes Res, 1998. 6(Suppl 2):51S-209S.
5. James W P, Astrup A, Finer N et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000;356:2119-2125.
6. Wadden TA, Berkowitz RI, Womble LG et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005;353:2111-2120.
7. Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab 2000;2:105-112.
8. Florentin M, Liberopoulos EN, Elisaf MS. Sibutramine-associated adverse effects: a practical guide for its safe use. Obes Rev 2008;9:378-387.
9. Torp-Pedersen C, Caterson I, Coutinho W et al.; SCOUT Investigators. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007;28:2915-2923.
10. Maggioni A P, Caterson I, Coutinho W et al.; SCOUT Investigators. Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial. J Cardiovasc Pharmacol 2008;52:393-402.
11. Smith IG, Goulder MA; Sibutramine Clinical Study 1047 Team. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001;50:505-512
12. Royal College of Physicians. Anti-obesity drugs: guidance on appropriate prescribing and management. A Report of the Nutrition Committee of the Royal College of Physicians. RCP: London, 2003.
13. Jordan J, Scholze J, Matiba B et al. Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes (Lond) 2005;29:509-516.
14. Heusser K, Tank J, Diedrich A et al. Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin Pharmacol Ther 2006;79:500-508.
15. Birkenfeld AL, Schroeder C, Boschmann M et al. Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation 2002;106:2459-2465.
16. Birkenfeld AL, Schroeder C, Pischon T et al. Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients\sibutramine and blood pressure. Clin Auton Res 2005;15: 200-206.
17. Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001;286:1331-1339.
18. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
19. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357.